TABLE 2.

Enhancement of splenic-macrophage FcγR MFI by treatment with estrogens

Estrogen dose (mg/kg)	% Enhancement (± SEM) of MFI ofa
	FcγR1-FcγR2	FcγR2
Et
0.002	17 ± 1*	11 ± 1*
0.005	25 ± 1	20 ± 1
0.010	38 ± 2	26 ± 1
0.100	46 ± 2	37 ± 2
1.000	68 ± 2	44 ± 2
M
0.25	15 ± 1*	10 ± 1*
0.50	30 ± 2	25 ± 1
1.00	41 ± 2	33 ± 2
5.00	59 ± 2	40 ± 2
Ct
0.25	16 ± 1*	12 ± 1*
0.50	25 ± 2	20 ± 2
1.00	42 ± 2	29 ± 2
5.00	56 ± 2	38 ± 3
Pm
0.05	16 ± 1*	11 ± 1*
0.10	24 ± 2	19 ± 1
0.50	39 ± 2	28 ± 2
1.00	50 ± 2	35 ± 2
Ep
1.00	15 ± 1*	10 ± 1*
2.50	30 ± 2	22 ± 2
5.00	47 ± 2	31 ± 2
E
1.00	16 ± 1*	11 ± 1*
2.50	32 ± 2	22 ± 2
5.00	46 ± 2	32 ± 2

^aAnimals were treated for 7 days with the indicated estrogens at different doses (in milligrams per kilogram per day). The percentages of enhancement of the MFIs (± SEM) for both guinea pig macrophage FcγRs, FcγR1-FcγR2 and FcγR2, over the MFI exhibited by sham controls are indicated. *, P < 0.01; P < 0.001 in all other cases.